March 9, 2014 | Israeli biomed company BiolineRX held a secondary public offering on Nasdaq. The offering is considered a success, as the company surpassed its goal of $21 million, raising $24 million. The company said that it will use the proceeds for clinical trials of its leukemia and celiac disease treatments.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments